GlassScriptPhysician profile
Milicent Robinson
NPI 1487044244
$3,494.64
in general payments reported to CMS, 2019-2025
28 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $419 · 2022: $618 · 2023: $595 · 2024: $715 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412 · Education: $45.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.65 |
| Education | $45.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.76 | 2021-2025 | |
| Sage Therapeutics, LLC | $447.66 | 2024-2025 | Zurzuvae |
| Organon LLC | $306.24 | 2021-2025 | Nexplanon, Jada System |
| Mayne Pharma Commercial LLC | $300.91 | 2021-2025 | |
| Astellas Pharma US INC | $267.90 | 2024-2025 | Veozah |
| Exeltis, USA INC. | $188.76 | 2021-2025 | Slynd |
| Millicent US INC | $184.31 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Shield Therapeutics INC | $141.31 | 2022-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $133.73 | 2023-2025 | Myfembree |
| Novo Nordisk INC | $130.66 | 2023-2024 | Wegovy, Saxenda |
| Bayer Healthcare Pharmaceuticals INC. | $123.75 | 2021-2025 | |
| Lilly USA, LLC | $92.94 | 2024-2025 | Zepbound, Mounjaro |
| Mylan Pharmaceuticals INC. | $83.35 | 2021-2022 | |
| Scynexis, INC. | $77.77 | 2022 | |
| Aspira Women'S Health INC | $60.83 | 2023 | Ova1 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $59.44 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Therapeuticsmd, INC. | $51.15 | 2021-2022 | |
| Agile Therapeutics, INC. | $50.42 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $48.87 | 2025 | Qelbree |
| Daiichi Sankyo INC. | $40.79 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $40.08 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $32.11 | 2023 | Seglentis |
| Evofem Biosciences, INC. | $25.46 | 2021-2022 | |
| Exact Sciences Corporation | $22.38 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $18.56 | 2025 | |
| Cepheid | $17.81 | 2025 | Genexpert |
| Myriad Women'S Health, INC. | $16.11 | 2023 | Myrisk |
| Optumhealth Care Solutions, LLC | $13.58 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milicent Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.